Back

Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair

30 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Interdependence of value and myocardial disease Intervention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Anne Rebecca Schoeber

University Medical Center of Mainz, Mainz (Germany)

7 More presentations in this session

Presentation thumbnail
Pressure-volume-strain-derived myocardial work: a novel prognostic marker in patients undergoing transcatheter aortic valve replacement
Doctor T. Turschl (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Assessment of reverse remodeling after transcatheter aortic valve replacement in the presence of established right ventricular damage
Doctor S. Peralta Merelo (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Incidence and prognostic impact of periprocedural myocardial injury during transcatheter aortic valve implantation
Doctor L. Waldschmidt (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac reverse remodeling on prognosis after transcatheter aortic valve replacement in patients with mixed aortic valve disease
Doctor Y. Saijo (Tokushima, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac damage and outcome in transcatheter aortic valve replacement patients
Mr R. Carter-Storch (Odense, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Interdependence of value and myocardial disease

The Event

Event poster

ESC Congress 2025

30 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Tricuspid regurgitation in the context of severe concomitant left-sided valvular heart disease: patients characteristics and long-term clinical and interventional outcomes
thumbnail
Congress Presentation
Clinical impact
thumbnail
Congress Presentation
Prognostic value of hemodynamically significant secondary tricuspid regurgitation in patients hospitalised for heart failure with preserved ejection fraction.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources